Literature DB >> 7770005

Apolipoprotein E genotype, Alzheimer's pathologies and related gene expression in the aged population.

F Oyama1, H Shimada, R Oyama, Y Ihara.   

Abstract

We have investigated the effect of genotypes of apolipoprotein E (ApoE) on the pathologies found in Alzheimer's disease (AD) and its related gene expression in 38 aged human brains obtained from consecutive autopsied cases. ApoE2/3, -3/3, -3/4, and -4/4 were typed in those aged brains, with ApoE3/3 being most prevalent. The AD pathologies were undetectable in ApoE2/3 brains, but were frequently observed in the other ApoE groups. In ApoE3/3 brains, 55%, 34%, and 24% of the cortical sections examined showed senile plaques (SPs), neurofibrillary tangles (NFTs), and cerebral amyloid angiopathy (CAA), respectively. In ApoE4/4 brains, the SP formation was significantly higher. The ApoE genotype neither affected ApoE, APP, or tau mRNA level, nor the differential expression of the latter two. These results suggest that ApoE4/4 accelerates and ApoE2/3 decelerates the development of the AD pathologies in the aged brain, but this is not through alterations of the APP and tau gene expression.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7770005     DOI: 10.1016/0169-328x(94)00233-5

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  12 in total

Review 1.  Apolipoprotein E as a Therapeutic Target in Alzheimer's Disease: A Review of Basic Research and Clinical Evidence.

Authors:  Yu Yamazaki; Meghan M Painter; Guojun Bu; Takahisa Kanekiyo
Journal:  CNS Drugs       Date:  2016-09       Impact factor: 5.749

2.  Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein epsilon 4 allele.

Authors:  T Arendt; C Schindler; M K Brückner; K Eschrich; V Bigl; D Zedlick; L Marcova
Journal:  J Neurosci       Date:  1997-01-15       Impact factor: 6.167

3.  Presence of ApoE ε4 allele associated with thinner frontal cortex in middle age.

Authors:  Christine Fennema-Notestine; Matthew S Panizzon; Wesley R Thompson; Chi-Hua Chen; Lisa T Eyler; Bruce Fischl; Carol E Franz; Michael D Grant; Amy J Jak; Terry L Jernigan; Michael J Lyons; Michael C Neale; Larry J Seidman; Ming T Tsuang; Hong Xian; Anders M Dale; William S Kremen
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

4.  AP-2β regulates amyloid beta-protein stimulation of apolipoprotein E transcription in astrocytes.

Authors:  Ximena S Rossello; Urule Igbavboa; Gary A Weisman; Grace Y Sun; W Gibson Wood
Journal:  Brain Res       Date:  2012-01-18       Impact factor: 3.252

Review 5.  Genomic variants, genes, and pathways of Alzheimer's disease: An overview.

Authors:  Adam C Naj; Gerard D Schellenberg
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2017-01       Impact factor: 3.568

Review 6.  The role of apolipoprotein E in Alzheimer's disease.

Authors:  Jungsu Kim; Jacob M Basak; David M Holtzman
Journal:  Neuron       Date:  2009-08-13       Impact factor: 17.173

7.  APOE epsilon2 is associated with intact cognition but increased Alzheimer pathology in the oldest old.

Authors:  Daniel J Berlau; María M Corrada; Elizabeth Head; Claudia H Kawas
Journal:  Neurology       Date:  2009-03-03       Impact factor: 9.910

8.  Differential associations of APOE-ε2 and APOE-ε4 alleles with PET-measured amyloid-β and tau deposition in older individuals without dementia.

Authors:  Gemma Salvadó; Michel J Grothe; Colin Groot; Alexis Moscoso; Michael Schöll; Juan Domingo Gispert; Rik Ossenkoppele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-01       Impact factor: 9.236

9.  Variation at APOE and STH loci and Alzheimer's disease.

Authors:  Lingjun Zuo; Christopher H van Dyck; Xingguang Luo; Henry R Kranzler; Bao-zhu Yang; Joel Gelernter
Journal:  Behav Brain Funct       Date:  2006-04-07       Impact factor: 3.759

10.  Factors determining disease duration in Alzheimer's disease: a postmortem study of 103 cases using the Kaplan-Meier estimator and Cox regression.

Authors:  R A Armstrong
Journal:  Biomed Res Int       Date:  2014-01-22       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.